LongeVC’s Post

In last week's newsletter "Where Tech Meets Bio": Weekly tech bio highlights; Seed Health Invests in AI-Driven Biology Platform to Enhance Microbiome Science; Novel Gen AI Platform for Preclinical Research; This Company's ML Model Predicts KRAS Inhibitor's Clinical Benefit in Patients with >80% Accuracy; Model Medicines Advances AI Drug Discovery in Antiviral and Oncology Fields; A Novel Quantum-assisted Approach to Designing Drugs From Fragments; Cancer Vaccines: insights from #AACR24 Mapping AI-driven drug candidates and targets (infographic) Read the newsletter via the link in the comments and subscribe to not miss future weekly insights about emerging technologies in the life sciences! #biopharmatrend #WhereTechMeetsBio #techbio

We are pleased to announce our new strategic partnership with KYAN Technologies and Alentis Therapeutics. Through this #collaboration, all three organizations will leverage their respective expertise and resources to advance Claudin-1 expression #research to new heights. KYAN Technologies will bring its cutting-edge Optim.AI™, which solves large and complex search spaces to identify and rank combination treatments across the spectrum of biological models. Alentis Therapeutics will contribute its extensive experience in disease research and #drug development, while we provide complex patient-derived cell culture models (PD3D®) and hyper-characterized models tailored specifically for CLDN1 expression studies and subsequent compound screening. This exciting research #partnership enables more precise and detailed insights into the role of #CLDN1 in #cancer, paving the way for novel therapeutic approaches. #partnership #AI #biotech #pressrelease #news #science #PD3D #cancertherapy #cancerresearch #cancertreatment

The mRNA-technology received worldwide attention during the COVID-19 pandemic. Meanwhile it is an established method in diagnostics which opens up new possibilities for the fight against cancer and other hereditary diseases.   However, until today the production of cell therapeutics has been manual or only partially automated, resulting in productivity and quality variability as well as extraordinarily high costs.   How can we change this?   The RNAuto project aims to provide a cost-effective, high-volume production of mRNAs, mRNA nanocarriers and mRNA-modified cells. By developing bioprocessing methods and production technologies we want to fully automate the production process of mRNA-based drugs and medicines. Consequently, individual therapies could be made available at an affordable price.   More information in our Annual Report 2022/23 page 22 👉 https://lnkd.in/ehq_6hRX   #makingthedifference | #Fraunhofer

Seven molecular glue startups looking to stick around in the biotech industry: Since molecular glues were discovered three decades ago, they have become a therapeutic option for treating several difference disease areas, including cancer and neurodegenerative disorders. Molecular glue refers to a small molecule that sticks two proteins together. These molecules were originally discovered by chance, but more recently scientists have been able to design them into a class of medicines, known as targeted protein degraders, destroying disease-causing proteins. Therefore, molecular glues are the newest promising solution to attacking targets that were previously labelled as ‘undruggable’. Now, there are a rising number of molecular glue companies hoping to show clinical success with their candidates. Discover more about these new therapeutics: #therapeutics #molecularbiology #lifesciences

🔍 Exciting news in biotech investments! These investments show the growing potential in biometrics. Great to see advancements across different health areas, from mental health to cancer treatment 🇺🇸 Spyre Therapeutics | $180 million PIPE | monoclonal antibodies | preclinical in inflammatory bowel disease 🇺🇸 Engrail Therapeutics | $157 million series B | precision neuroscience | phase 2 in generalized anxiety disorder 🇨🇦 Cybin Inc | $150 million PIPE | mental healthcare | phase 2 in major depressive disorder 🇩🇪 Tubulis GmbH | €128 million ($138.75 million) series B2 | antibody drug conjugates | preclinical in multiple solid tumors 🇺🇸 Unicycive Therapeutics | $50 million PIPE | kidney disease treatments | phase 1 in hyperphosphatemia 🇬🇧 Relation | $35 million seed | multi omics for drug discovery | discovery in osteoporosis 🇸🇪 Asgard Therapeutics | €30 million ($32.53 million) series A | cancer immunotherapies | preclinical in cancer 🇬🇧 Mission Therapeutics | £25.2 million ($32 million) | deubiquitylating enzyme inhibitors | phase 2 in cardiac surgery-associated kidney injury 🇺🇸 Elicio Therapeutics | $6 million PIPE | immunotherapies | phase 2 in pancreatic ductal adenocarcinoma

The Future of Diagnostics and the Impact on Deals Listen to PharmaVentures' latest podcast: https://lnkd.in/d6BB-6wE Listen as Andreas Katsiamides, Ph.D. talks with Adrian Dawkes about the future of diagnostics and the impact on deals. They discuss: - Technological advances in diagnostics, such as artificial intelligence (AI), next-generation sequencing (NGS) and polymerase chain reaction (PCR) testing - Its application to specific medical models and therapy areas – including personalised medicine, oncology, and Alzheimer’s - Key players in the area, and their commercial models - The importance of diagnostics working hand-in-hand with therapeutics - Licensing and M&A transactions, and the potential deal values in the future #Diagnostics  #Cancer #Oncology #AlzheimersDisease #PrecisionMedicine #PersonalisedMedicine #CompanionDiagnostics #Licensing #Partnering #MergersandAcquisitions #AI #Valuations #MedTech #Podcast #JPMWeek #JPM24 #BiotechShowcase #TheDealExperts

Which will be the future of oncology? Yesterday at #VivaTech, while searching for biotechnological innovations, I found the Gustave Roussy tech transfer booth. Please, take a look at three of the presented proposals: Orakl Oncology Integrating AI-powered analysis of Patient-Derived Organoids for better, faster, and cost-effective treatments. It will involve the development of an automated lab system to license it to other healthcare centers around the globe. Cure51 There is a 3% of exceptional patients who survive the most lethal cancers. By characterizing their exceptional traits, they plan to find out which mechanisms and biomarkers are related to this "miracle." A simple but fascinating strategy that can lead to several business plans and is definitely a startup to keep an eye on. Elikya Therapeutics Focusing on the improvement of Antibody Drug Conjugates (ADCs) in oncology based on its own toxic payloads. Designed to fight against cancer cells and the tumoral microenvironment with a differentiated mechanism of action. A big thank you to the presenters, and I hope to see more technological approaches to biology in the future. Looking forward to connecting with fellow attendees. Feel free to reach out if you want to discuss AI and biotechnology integration further! #OncologyResearch #Biotechnology #VivaTech #CancerResearch #BiotechInnovations #HealthTech #Startups #HealthcareInnovation

EvlaBio AG is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a therapeutic monoclonal antibody (mAb) targeting the FGF23/FGFR4 pathway for the treatment of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction (HFpEF) in the setting of chronic kidney disease (CKD). LVH and HFpEF occur in CKD patients as a consequence of FGF23/FGFR4 overdrive. Hence, blocking the FGF23/FGFR4 interaction has the potential to prevent cardiac hypertrophy and ameliorate heart failure in patients with CKD. The serviceable obtainable market of patients with LVH due to FGF23/FGFR4 overdrive ranges between 5 and 6 M in the seven major markets, representing a substantial commercial opportunity. Based on its underlying mechanism of action, the EvlaBio approach is expected to be hemodynamically neutral. This is a critical differentiating feature from currently available treatment options. With respect to modality, the EvlaBio will be the first biologic developed for this indication, and it has the potential to be a first in class and first in indication therapy.  We also have a biomarker strategy leveraging specific features of target biology in place, ensuring effective clinical trial design. Meet EvlaBio AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW